Looking to grow through franchising route: Ameera Shah
It is an absolute surprise to see this beauty choose a rare profession of pathology and diagnostic over a pronounced career in glamour; similar to choosing a bitter pill over a sweet one, while defying the very fact that beauty and brains can never agree to be together. Having dared, the mutiny then marched into the domain of the other gender to take reins of Metropolis Healthcare Ltd as the CEO and MD and propelled the company to greater heights in a short time. Setting precedent, she is undoubtedly defining future for Indian women. In a chat with us, Ameera Shah talks enthusiastically about her company’s brilliant achievements and their future plans.
Tell us about Metropolis Healthcare Ltd.
Metropolis is a chain of diagnostic centres and we have around 60 pathological laboratories in India, South Africa, Nigeria, Srilanka, UAE, Nepal, Bangladesh and Mauritius. With over 4000 plus routine, specialized and highly specialized investigations that uses over 100 different technologies including Biochip and DNA sequencing, we have revolutionized the way Healthcare industry works. Moreover, while rendering services like Referral Pathology and Imaging Services, Preventive Health Checkups, Central Laboratory for Clinical Trials, Hospital Laboratory Management Services, Remote Pathology Testing Services, Site management Organisation and Home Health Services, we strive to give best value for money so we insist that people ask for latest technology, ethical practices and complete satisfaction.
What is your mission?
We want to become the most preferred partner for the Government of India with atleast 1 lab in each state and to be in a position to successfully exploit MBPO opportunities in Europe, UK and USA, so that we can create an organization of equal opportunities for all employees and share corporate social responsibility and an organsiation propelled by research and knowledge. As we attempt the above, we want to be a leader in India, Sri Lanka and rest of south Asia and feature in top three players in South Africa, South East Asia and Middle East.
What is your USP?
We are leaders across countries in pathology labs. We are a quality conscious company. We have a reputation and we have total accreditation for quality which makes us a company of global standards. Unparallel customer service, innovation like Home Health where in we reach you at home and a unique loyalty program make us a preferred choice of customers. We thrive on accuracy, timely reports and quality.
How has the company grown under your able guidance?
Since I took charge of the company, Metropolis has grown from a single laboratory status in 2002 to a fully integrated multinational chain of 60 diagnostic centre across South Asia, Middle East and Africa in 2010 while creating substantial JVs in Srilanka, UAE and South Africa. Metropolis has become a well respected healthcare brand, catering to more than 10,000 small labs, nursing homes and hospitals, over 20,000 consultants and processes doing more than 12 million test annually. Moreover, you may witness the glory that has come in the past 9 years through expansion into new services like Clinical Research, Hospital Lab Management and Wellness Solutions. We are always exploring and adopting cutting edge, new technologies and services that opens up new revenue streams and strategically position the company as a leader.
Personally, I have been voted as “The Young entrepreneur of the Year” in India. I am also the Secretary of IAPL (Indian association and pathology Laboratories) and a member of most prominent diagnostic and healthcare committee.
Who are your target customers?
All medical specialties, analytical laboratories, clinical laboratories, hospitals, research institutions, veterinary medicine, pharmaceuticals, clinical research Organizations, IVF centers, corporates, insurance companies and direct patients are our customers and we intend to increase this base.
What are your expansion plans?
By increasing the network of franchisees and collection centres in India and abroad in the next 6 months.